

**AMENDMENTS TO THE CLAIMS**

This listing of the claims replaces all prior listings and versions:

1. (canceled)
2. (currently amended): An expression cassette comprising  
a polynucleotide sequence operably linked to a promoter, wherein the polynucleotide  
sequence comprises a nucleotide sequence having at least 90% sequence identity to full-length  
SEQ ID NO:3 and encodes an immunogenic HIV *Gag* polypeptide that elicits a *Gag*-specific  
immune response.
3. (canceled)
4. (currently amended): An expression cassette comprising  
a polynucleotide sequence operably linked to a promoter, wherein the polynucleotide  
sequence comprises a nucleotide sequence having at least 90% sequence identity to full-length  
SEQ ID NO:4 and encodes an immunogenic HIV *Gag* polypeptide that elicits a *Gag*-specific  
immune response.
5. (previously presented): The expression cassette of claim 2, wherein the nucleotide  
sequence encoding said HIV *Gag* polypeptide consists of SEQ ID NO:3.
6. (previously presented): The expression cassette of claim 4, wherein the nucleotide  
sequence encoding said HIV *Gag* polypeptide consists of SEQ ID NO:4.
7. (previously presented): The expression cassette of claim 2 or claim 4, wherein said  
polynucleotide sequence further includes a nucleotide sequence encoding an HIV *protease*  
polypeptide.
8. (previously presented): The expression cassette of claim 2 or claim 4, wherein said  
polynucleotide sequence further includes a nucleotide sequence encoding an HIV *polymerase*  
polypeptide.

9. (previously presented): The expression cassette of claim 2 or claim 4, wherein said polynucleotide sequence further includes a nucleotide sequence encoding an HIV *polymerase* polypeptide, wherein the nucleotide sequence encoding the HIV *polymerase* polypeptide is modified by deletions of coding regions encoding reverse transcriptase and integrase.

10. (previously presented): The expression cassette of claim 9, wherein said polynucleotide sequence encodes a polypeptide comprising T-helper cell and CTL epitopes.

11 to 23. (canceled)

24. (previously presented): A recombinant expression system for use in a selected host cell, comprising, the expression cassette of claim 2 or claim 4, and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the selected host cell.

25. (original): The recombinant expression system of claim 24, wherein said control elements are selected from the group consisting of a transcription promoter, a transcription enhancer element, a transcription termination signal, polyadenylation sequences, sequences for optimization of initiation of translation, and translation termination sequences.

26. (previously presented): The recombinant expression system of claim 25, wherein said transcription promoter is selected from the group consisting of CMV, CMV+intron A, SV40, RSV, HIV-Ltr, MMLV-ltr, and metallothionein.

27. (previously presented): A cell comprising the expression cassette of claim 2 or claim 4, and wherein said polynucleotide sequence is operably linked to control elements compatible with expression in the selected cell.

28. (original): The cell of claim 27, wherein the cell is a mammalian cell.

29. (original): The cell of claim 28, wherein the cell is selected from the group consisting of BHK, VERO, HT1080, 293, RD, COS-7, and CHO cells.

30. (original): The cell of claim 29, wherein said cell is a CHO cell.

31. (original): The cell of claim 27, wherein the cell is an insect cell.
32. (original): The cell of claim 31, wherein the cell is either *Trichoplusia ni* (Tn5) or Sf9 insect cells.
33. (original): The cell of claim 27, wherein the cell is a bacterial cell.
34. (original): The cell of claim 27, wherein the cell is a yeast cell.
35. (original): The cell of claim 27, wherein the cell is a plant cell.
36. (original): The cell of claim 27, wherein the cell is an antigen presenting cell.
37. (previously presented): The cell of claim 36, wherein the antigen presenting cell is a lymphoid cell is selected from the group consisting of macrophage, monocytes, dendritic cells, B-cells, T-cells, stem cells, and progenitor cells thereof.
38. (original): The cell of claim 27, wherein the cell is a primary cell.
39. (original): The cell of claim 27, wherein the cell is an immortalized cell.
40. (original): The cell of claim 27, wherein the cell is a tumor-derived cell.
41. (currently amended): A composition for generating an immunological response, comprising:  
the expression cassette of claim 1 2 or claim 3 4.
42. (original): The composition of claim 41, further comprising a *Gag* polypeptide.
43. (original): The composition of claim 41, further comprising an adjuvant.
- 44 to 48. (canceled)

49. (previously presented): A method of generating an immune response in a subject, comprising,

introducing the composition of claim 41 into said subject under conditions that are compatible with expression of said expression cassette in said subject.

50. (original): The method of claim 49, wherein said expression cassette is introduced using a gene delivery vector.

51. (original): The method of claim 50, wherein the gene delivery vector is a non-viral vector.

52. (original): The method of claim 50, wherein said gene delivery vector is a viral vector.

53. (original): The method of claim 52, wherein said gene delivery vector is a Sindbis-virus derived vector.

54. (original): The method of claim 52, wherein said gene delivery vector is a retroviral vector.

55. (original): The method of claim 52, wherein said gene delivery vector is a lentiviral vector.

56. (original): The method of claim 49, wherein said composition delivered using a particulate carrier.

57. (original): The method of claim 49, wherein said composition is coated on a gold or tungsten particle and said coated particle is delivered to said subject using a gene gun.

58. (original): The method of claim 49, wherein said composition is encapsulated in a liposome preparation.

59. (previously presented): The method of claim 49, wherein said subject is a mammal.

60. (original): The method of claim 59, wherein said mammal is a human.

61 to 62. (canceled)

63. (previously presented): The method of claim 49, where the method further comprises administration of an HIV polypeptide.

64. (original): The method of claim 63, wherein administration of the polypeptide to the subject is carried out before introducing said expression cassette.

65. (original): The method of claim 63, wherein administration of the polypeptide to the subject is carried out concurrently with introducing said expression cassette.

66. (original): The method of claim 63, wherein administration of the polypeptide to the subject is carried out after introducing said expression cassette.

67. (canceled)

68. (previously presented): An expression cassette comprising the polynucleotide sequence of SEQ ID NO:3.

69. (previously presented): An expression cassette comprising the polynucleotide sequence of SEQ ID NO:4.

70. (original): The expression cassette of claim 68, further comprising a nucleotide sequence encoding an HIV protease polypeptide.

71. (original): The expression cassette of claim 69, further comprising a nucleotide sequence encoding an HIV protease polypeptide.

72. (original): The expression cassette of claim 68, further comprising a nucleotide sequence encoding an HIV polymerase polypeptide.

73. (original): The expression cassette of claim 69, further comprising a nucleotide sequence encoding an HIV polymerase polypeptide.

74. (previously presented): A composition for generating an immunological response in a mammal comprising the expression cassette of claim 68 or claim 69.

75. (previously presented): A method of generating an immune response in a mammal, the method comprising the step of intramuscularly administering the expression cassette of claim 68 or claim 69 to said mammal.